Literature DB >> 26137412

Natural Killer cell control of BRAFV600E mutant melanoma during targeted therapy.

Lucas Ferrari de Andrade1, Shin Foong Ngiow2, Ludovic Martinet3, Mark J Smyth4.   

Abstract

Pharmacologic inhibition of the mutant BRAFV600E protein in advanced BRAFV600E melanoma results in a high proportion of patients that respond, but few with durable responses. We have recently revealed that Natural Killer (NK) cells play an essential role in the BRAFV600E inhibitor control of melanoma metastases in mice that may be therapeutically exploited to help overcome drug resistance.

Entities:  

Keywords:  BRAF; NK cells; cancer immunotherapy; metastases; resistance

Year:  2015        PMID： 26137412      PMCID： PMC4485837          DOI： 10.1080/2162402X.2014.998119

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Genome-scale CRISPR-Cas9 knockout screening in human cells.

Authors:  Ophir Shalem; Neville E Sanjana; Ella Hartenian; Xi Shi; David A Scott; Tarjei Mikkelson; Dirk Heckl; Benjamin L Ebert; David E Root; John G Doench; Feng Zhang
Journal:  Science       Date:  2013-12-12       Impact factor: 47.728

3.  Biological behavior of malignant melanoma cells correlated to their survival in vivo.

Authors:  I J Fidler
Journal:  Cancer Res       Date:  1975-01       Impact factor: 12.701

4.  Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.

Authors:  Lucas Ferrari de Andrade; Shin F Ngiow; Kimberley Stannard; Sylvie Rusakiewicz; Murugan Kalimutho; Kum Kum Khanna; Siok-Keen Tey; Kazuyoshi Takeda; Laurence Zitvogel; Ludovic Martinet; Mark J Smyth
Journal:  Cancer Res       Date:  2014-10-28       Impact factor: 12.701

5.  The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.

Authors:  Eric W Joseph; Christine A Pratilas; Poulikos I Poulikakos; Madhavi Tadi; Weiqing Wang; Barry S Taylor; Ensar Halilovic; Yogindra Persaud; Feng Xing; Agnes Viale; James Tsai; Paul B Chapman; Gideon Bollag; David B Solit; Neal Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-28       Impact factor: 11.205

6.  Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Authors:  Deborah A Knight; Shin Foong Ngiow; Ming Li; Tiffany Parmenter; Stephen Mok; Ashley Cass; Nicole M Haynes; Kathryn Kinross; Hideo Yagita; Richard C Koya; Thomas G Graeber; Antoni Ribas; Grant A McArthur; Mark J Smyth
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

7.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Authors:  James Tsai; John T Lee; Weiru Wang; Jiazhong Zhang; Hanna Cho; Shumeye Mamo; Ryan Bremer; Sam Gillette; Jun Kong; Nikolas K Haass; Katrin Sproesser; Ling Li; Keiran S M Smalley; Daniel Fong; Yong-Liang Zhu; Adhirai Marimuthu; Hoa Nguyen; Billy Lam; Jennifer Liu; Ivana Cheung; Julie Rice; Yoshihisa Suzuki; Catherine Luu; Calvin Settachatgul; Rafe Shellooe; John Cantwell; Sung-Hou Kim; Joseph Schlessinger; Kam Y J Zhang; Brian L West; Ben Powell; Gaston Habets; Chao Zhang; Prabha N Ibrahim; Peter Hirth; Dean R Artis; Meenhard Herlyn; Gideon Bollag
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

Review 8.  Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Mark J Smyth; Guido Kroemer
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

9.  Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid).

Authors:  K Dorshkind; S B Pollack; M J Bosma; R A Phillips
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

10.  Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.

Authors:  Douglas B Johnson; Erika K Wallender; Daniel N Cohen; Sunaina S Likhari; Jeffrey P Zwerner; Jennifer G Powers; Lisa Shinn; Mark C Kelley; Richard W Joseph; Jeffrey A Sosman
Journal:  Cancer Immunol Res       Date:  2013-12       Impact factor: 11.151
  10 in total
  4 in total

1.  Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.

Authors:  Laetitia Fend; Sylvie Rusakiewicz; Julien Adam; Bérangère Bastien; Anne Caignard; Meriem Messaoudene; Christina Iribarren; Isabelle Cremer; Aurélien Marabelle; Christophe Borg; Michaela Semeraro; Luc Barraud; Jean-Marc Limacher; Alexander Eggermont; Guido Kroemer; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

2.  Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis.

Authors:  Eva M Putz; Camille Guillerey; Kevin Kos; Kimberley Stannard; Kim Miles; Rebecca B Delconte; Kazuyoshi Takeda; Sandra E Nicholson; Nicholas D Huntington; Mark J Smyth
Journal:  Oncoimmunology       Date:  2017-02-07       Impact factor: 8.110

3.  CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity.

Authors:  Amelia Roman Aguilera; Viviana P Lutzky; Deepak Mittal; Xian-Yang Li; Kimberley Stannard; Kazuyoshi Takeda; Günter Bernhardt; Michele W L Teng; William C Dougall; Mark J Smyth
Journal:  Oncoimmunology       Date:  2018-02-01       Impact factor: 8.110

4.  NK cell heparanase controls tumor invasion and immune surveillance.

Authors:  Eva M Putz; Alyce J Mayfosh; Kevin Kos; Deborah S Barkauskas; Kyohei Nakamura; Liam Town; Katharine J Goodall; Dean Y Yee; Ivan Kh Poon; Nikola Baschuk; Fernando Souza-Fonseca-Guimaraes; Mark D Hulett; Mark J Smyth
Journal:  J Clin Invest       Date:  2017-06-05       Impact factor: 14.808
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.